Pfizer and Merck KGaA are officially fourth to market with their checkpoint inhibitor avelumab—but first with to target a rare, aggressive form of skin cancer.

U.S. government watchdogs plan to probe the FDA's orphan drug policies after Marathon's high-profile pricing scandal.

AstraZeneca’s Lynparza honed its edge in ovarian cancer on Tuesday, just in time to help preserve its lead in the marketplace.

​​​​​​​Add Pfizer to the list of the companies facing a governmental investigation about its ties to copay assistance charities.

Pfizer scored new Crohn’s data that could give its Remicade biosimilar, Inflectra, more oomph for its market-share fight, one of the first U.S. head-to-heads…

AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint…

President Trump told Robert Kennedy Jr. he won't "back down" from plans to create vax safety commission, despite guaranteed "uproar"…

Will Valeant price its new psoriasis med at a discount to rivals to reflect its hefty suicide risk-management program? And if not, can it still compete?…

Regulatory